Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of Oncovex gene therapy for melanoma and other cancers that have spread to the skin
This trial was looking at a type of cancer vaccine called OncovexGM-CSF for melanoma skin cancer and other cancers that had spread to the skin. It was a very early trial that tested this treatment for the first time in people.
More about this trial
The treatment used a virus which had been changed to make a natural substance called
The researchers hoped that the virus would kill cancer cells and the GM-CSF would boost the immune system to help fight the cancer.
So that the researchers could easily see the effect the virus had on cancer, the trial was only open to people who had nodules (lumps) of cancer on their skin. As well as melanoma skin cancer, skin nodules can develop in bowel cancer, head and neck cancer, oesophageal cancer, pancreatic cancer, breast cancer and stomach cancer.
Doctors injected the treatment directly into the tumours in the skin (
The aim of the trial was to see how the treatment affected cancer cells in the skin nodules and how safe it was.
Summary of results
The researchers found that Oncovex could be safely injected into skin nodules and some cancers responded to the treatment.
The trial recruited 30 people.
13 people had a single injection of Oncovex. The first 4 people had a low dose. As they didn’t have any side effects other than mild flu like symptoms, the next 4 people had a higher dose and so on, for 3 different doses.
48 hours after the injection, the researchers took a sample of cells from the treated skin nodule using a fine needle (
17 people had 3 injections, between 1 and 3 weeks apart. Again, the researchers looked at 3 different doses. They took a biopsy after the last injection.
The trial team had results for 26 patients. In 14 people, the biopsy taken after treatment contained cancer cells that had died
- In 3 people the cancer stayed the same size – researchers call this
- In 6 people, skin nodules got smaller (flatter), but the cancer continued to grow elsewhere in the body
- In 17 people, the cancer did not respond to the treatment
The most common side effects were redness or swelling at the injection site and flu like symptoms.
The researchers found that having more than one injection worked better than having a single injection. They used their results to work out the best dose to use in future trials of Oncovex for specific types of cancer.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Charles Coombes